Our research group focus is divided between two main fields:
In the proteomics method development field, our aim is improving the analytical depth and quantitative accuracy in shotgun proteomics. In addition, we develop methods for functional proteomics such as analysis of post-translational modification of proteins, subcellular localization of proteins and drug response profiling at the protein level. Further, we are involved in projects where methods for proteogenomics are developed and applied, as well as methods for statistical analysis of MS data.
In the cancer proteomics field, our current research is aiming for improvement of cancer therapy, treatment prediction and combination therapy, specifically in the context of lung cancer. This research is based on in-depth analysis of the molecular response to targeted therapies in model cell lines for identification of candidate predictive biomarkers and effective combination therapies. For validation of candidate combination therapies, cell-based drug screening is used. For clinical evaluation of candidate biomarkers both in-depth profiling of clinical lung cancer samples and targeted assays are used.